Please find the Symposium Replay on:

SESSION 1
Worldwine trends for allogeneic and car t-cells
Chair: M. Mohty

Welcome introductions
D. Blaise & M. Mohty

Chinese perspective
X. J. Huang

European perspective
A. Sureda

US perspective
B. Savani

Impact of Covid pandemic on cellular therapy
C. Chabannon

Questions & answers

Keynote lecture
Chair: D. Blaise

PTCY 20 years later: what a journey!
L. Luznik

Car-T cells: already 10 years!
M. Mohty

Questions & answers

SESSION 2
Solved or unsolved issues in HSCT?
Chair: R. Devillie

The best donor in haplo HSCT?
S. Fürst

MAC or RIC?
A. Nagler

BM or PBSC?
A. Bazarbachi

Novel alkylating agents in conditioning.
D. Blaise

Questions & answers

Christian Cailliot Award

SESSION 3
Old issues and new perspectives
Chair: N-C. Gorin

New reduce toxicity conditioning of melphalan-busulfan and fludarabine in patients with AML/MDS.
J. Hu

The place of fecal microbiota in HSCT.
F. Malard

Immmunotherapy with NK cells.
R. Devillier

What could be the next utility for cord blood?
S. Parmar

Questions & answers

SESSION 4
Personalized medecine
Chair: S. Fürst

How to personalize CDT in haemoglobinopathies transplant?
B. Andersson

Dose adapted drugs for CDT.
J. Boelens

HSCT personalized approach in older patients.
S. Harbi

Questions & answers

SESSION 5
Geneticallly modified cells (part 1)
Chair: F. Malard

Relapse prevention post Car-T cells treatment: Allo HSCT?
H. Huang

Relapse after post Car-T cells treatment: second infusion?
J. Gauthier

Car T-cells or bispecific MoABs for all?
E. Brissot

Multiple myeloma: the next challenge?
I. Yakoub-Agha

Questions & answers

SESSION 6
Generically modified cells (part 2)
Chair: I. Yakoub-Agha

Point of care strategy for Car-T cells: a valid option?
A. Urbano-Ispizua

The evolution of the Covid-19 pandemic in a US hematological malignancy and cell therapy unit: from prevention to infection to vaccination.
F. B. Petersen

Cellular immunotherapy in low-income countries: myth or reality?
R. Gabus

Questions & answers

SESSION 7
Challenging questions
Chair: E. Brissot

Relapse prediction after mismatch transplant.
L. Vago

Post transplant treatments: for which patients?
I. Gojo

How can we use MRD assessments before allo-SCT in acute myeloid leukemia?
N. Vey

Allogeneic HSCT for NHL at the time of Car-T cells.
L. Castagna

Questions & answers

Conclusive remarks

Enter your
text here